home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

CRLF2 Defects in Down Syndrome-Associated Leukemia

 
  November, 2 2009 8:59
your information resource in human molecular genetics
 
     

A chromosomal alteration that fuses the P2RY8 and CRLF2 genes is found in individuals with B-progenitor acute lymphoblastic leukemia (ALL) and ALL associated with Down syndrome (DS), according to a new study published online in Nature Genetics.

ALL is the most common childhood cancer, with a cure rate of 85% in children. Children with DS are approximately 10-20 times more likely to develop leukemia than non-DS children.

Charles Mullighan and colleagues report that a recurrent chromosomal deletion that leads to the P2RY8-CRLF2 fusion is found in 7% of individuals with B-progenitor ALL and 53% of individuals with Down syndrome-associated ALL. The fusion leads to elevated activity of the CRLF2 gene, which may contribute to the increased risk of ALL in children with DS.

Author Contact:

Charles G. Mullighan (St. Jude Children's Research Hospital, Memphis, TN, USA)
E-mail: charles.mullighan@stjude.org

Abstract available online.

(C) Nature Genetics press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.